SLCO1B1 genetic variants, long-term low-density lipoprotein cholesterol levels and clinical events in patients following cardiac catheterization. (April 2015)

• Record Type: Journal Article
• Authors: Li, Josephine H; Suchindran, Sunil; Shah, Svati H; Kraus, William E; Ginsburg, Geoffrey S; Voora, Deepak
• Is Part Of: Pharmacogenomics. Volume 16:Number 5(2015)
• Page Start: 449
• Page End: 458
• Publication Date: 2015-04
• Subjects: cardiovascular events -- low-density lipoprotein cholesterol -- myocardial infarction -- pharmacogenetics -- rs4149056 -- rs2306283 -- SLCO1B1 -- statin; Pharmacogenomics -- Periodicals; 615.1
• DOI: 10.2217/pgs.15.2
• Languages: English
• ISSNs: 1462-2416

Abstract

Aim: SLCO1B1 variants are associated with intermediate outcomes that may increase risk of death/myocardial infarction (MI) in statin-treated patients.Patients & methods: In high-risk Caucasians undergoing cardiac catheterization, we tested the association between rs4149056/625T>C and rs2306283/492A>G with low-density lipoprotein cholesterol (LDL-c) over 3 years (n = 1402) and death/MI over 6 years (n = 2994), accounting for statin use or type during follow-up.Results: Carriers of the rs4149056 C allele had 6.2 ± 1.7 mg/dl higher LDL-c per C allele (p < 0.001) but were not at higher risk for death/MI (p = 0.9). We found no associations between rs2306283 and LDL-c or death/MI (p > 0.6).Conclusion: Functional SLCO1B1 variants are not associated with death/MI in patients commonly treated with statins, despite higher LDL-c in carriers of the rs4149056 C allele. Original submitted 3 November 2014; Revision submitted 5 January 2015